Neutralisation of adeno-associated virus transduction by human vitreous humour

被引:6
作者
Andrzejewski, Slawomir [1 ,2 ]
Moyle, Peter M. [3 ]
Stringer, Brett W. [1 ,2 ]
Steel, Jason C. [4 ]
Layton, Christopher J. [1 ,2 ]
机构
[1] LVF Ophthalmol Res Ctr, Translat Res Inst, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Fac Med, Greenslopes Clin Sch, Greenslopes, Qld 4120, Australia
[3] Univ Queensland, Sch Pharm, Woolloongabba, Qld 4102, Australia
[4] CQ Univ, Sch Hlth Med & Appl Sci, North Rockhampton, Qld 4702, Australia
关键词
INTRAVITREAL INJECTION; RHESUS-MONKEYS; SERUM-PROTEINS; SEROTYPES; ANTIBODIES; AAV; PHARMACOKINETICS; RANIBIZUMAB; BEVACIZUMAB; GALECTIN-3;
D O I
10.1038/s41434-020-0162-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neutralising antibodies (NAbs), caused by past adeno-associated virus (AAV) infection, represent a critical challenge for AAV-mediated gene therapy, with even low NAb titres capable of inhibiting gene transfer, however in protein-rich environments such as the vitreous it is expected that other constituents could also interact with the transduction process. Inhibition of AAV2/2, AAV2/5, AAV2/6 and AAV2/8 transduction by human vitreous humour (VH) obtained from 80 post-mortem eye cups was investigated in this report, with clinically relevant vitreous dilutions as low as 1:2. Unexpectedly, the highest prevalence of inhibition of transduction was observed against AAV2/6, with 66% of tested samples displaying neutralisation at a 1:2 VH dilution. Only two samples showed inhibition of AAV2/8, indicating this serotype is an attractive vector for use in non-vitrectomised eyes of unscreened individuals. Levels of anti-AAV NAbs observed in the VH were much lower than previously observed in serum of a similar Australian population. Among ten tested eye cup pairs, we observed only small variation in anti-AAV NAbs levels between the left and right eye cups. Interaction with 1:2 diluted VH had an augmentation effect on AAV2/8 transduction (p = 0.004), a phenomenon which was not due to albumin or transferrin and which, if developed, might benefit the use of AAV2/8 in clinical settings.
引用
收藏
页码:242 / 255
页数:14
相关论文
共 53 条
  • [1] Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus
    Andrzejewski, Slawomir
    Murali, Aparna
    Ramlogan-Steel, Charmaine
    Edwards, Katie P.
    Efron, Nathan
    Steel, Jason C.
    Layton, Christopher J.
    [J]. GENE THERAPY, 2019, 26 (06) : 250 - 263
  • [2] [Anonymous], 2012, MEDIAT INFLAMM, DOI DOI 10.1155/2012/148039
  • [3] Vitreous humor analysis for the detection of xenobiotics in forensic toxicology: a review
    Bevalot, Fabien
    Cartiser, Nathalie
    Bottinelli, Charline
    Fanton, Laurent
    Guitton, Jerome
    [J]. FORENSIC TOXICOLOGY, 2016, 34 (01) : 12 - 40
  • [4] Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
    Boutin, Sylvie
    Monteilhet, Virginie
    Veron, Philippe
    Leborgne, Christian
    Benveniste, Olivier
    Montus, Marie Francoise
    Masurier, Carole
    [J]. HUMAN GENE THERAPY, 2010, 21 (06) : 704 - 712
  • [5] Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    Brown, David M.
    Kaiser, Peter K.
    Michels, Mark
    Soubrane, Gisele
    Heier, Jeffrey S.
    Kim, Robert Y.
    Sy, Judy P.
    Schneider, Susan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) : 1432 - 1444
  • [6] Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses
    Calcedo, Roberto
    Vandenberghe, Luk H.
    Gao, Guangping
    Lin, Jianping
    Wilson, James M.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (03) : 381 - 390
  • [7] Emerging Issues in AAV-Mediated In Vivo Gene Therapy
    Colella, Pasqualina
    Ronzitti, Giuseppe
    Mingozzi, Federico
    [J]. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2018, 8 : 87 - 104
  • [8] CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
  • [9] Inner Limiting Membrane Barriers to AAV-mediated Retinal Transduction From the Vitreous
    Dalkara, Deniz
    Kolstad, Kathleen D.
    Caporale, Natalia
    Visel, Meike
    Klimczak, Ryan R.
    Schaffer, David V.
    Flannery, John G.
    [J]. MOLECULAR THERAPY, 2009, 17 (12) : 2096 - 2102
  • [10] Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy
    de Moraes, Gabriela
    Layton, Christopher J.
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 44 (09) : 838 - 852